138 related articles for article (PubMed ID: 38523255)
1. Low-dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia.
Ramakrishnan R; Munir F; Quesada AE; Hitzler J; Cuglievan B
Pediatr Blood Cancer; 2024 Jun; 71(6):e30974. PubMed ID: 38523255
[No Abstract] [Full Text] [Related]
2. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
Li X; Dong Y; Li Y; Ren R; Wu W; Zhu H; Zhang Y; Hu J; Li J
BMC Cancer; 2019 Aug; 19(1):819. PubMed ID: 31429724
[TBL] [Abstract][Full Text] [Related]
3. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
4. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
5. Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.
Leonard SM; Perry T; Woodman CB; Kearns P
PLoS One; 2014; 9(1):e87475. PubMed ID: 24489920
[TBL] [Abstract][Full Text] [Related]
6. Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis.
Stone A; Zukerman T; Flaishon L; Yakar RB; Rowe JM
Leuk Res; 2019 Jul; 82():36-42. PubMed ID: 31152922
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
8. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
9. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.
Taga T; Shimomura Y; Horikoshi Y; Ogawa A; Itoh M; Okada M; Ueyama J; Higa T; Watanabe A; Kanegane H; Iwai A; Saiwakawa Y; Kogawa K; Yamanaka J; Tsurusawa M
Pediatr Blood Cancer; 2011 Jul; 57(1):36-40. PubMed ID: 21557456
[TBL] [Abstract][Full Text] [Related]
10. Phase 1-2 safety, efficacy and pharmacokinetic study of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukaemia.
Kearns P; Zwaan CM; Reinhardt D; Gibson B; Moreno L; Nysom K; Nakahara S; Huang F; Zhou W; Parasrampuria DA; Nemat S
Br J Haematol; 2019 Aug; 186(3):e7-e11. PubMed ID: 30847896
[No Abstract] [Full Text] [Related]
11. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia.
Ritchie EK; Feldman EJ; Christos PJ; Rohan SD; Lagassa CB; Ippoliti C; Scandura JM; Carlson K; Roboz GJ
Leuk Lymphoma; 2013 Sep; 54(9):2003-7. PubMed ID: 23270581
[TBL] [Abstract][Full Text] [Related]
12. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
Magina KN; Pregartner G; Zebisch A; Wölfler A; Neumeister P; Greinix HT; Berghold A; Sill H
Blood; 2017 Aug; 130(7):946-948. PubMed ID: 28679736
[No Abstract] [Full Text] [Related]
13. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
Kantarjian HM; Thomas XG; Dmoszynska A; Wierzbowska A; Mazur G; Mayer J; Gau JP; Chou WC; Buckstein R; Cermak J; Kuo CY; Oriol A; Ravandi F; Faderl S; Delaunay J; Lysák D; Minden M; Arthur C
J Clin Oncol; 2012 Jul; 30(21):2670-7. PubMed ID: 22689805
[TBL] [Abstract][Full Text] [Related]
14. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.
Ravandi F; Issa JP; Garcia-Manero G; O'Brien S; Pierce S; Shan J; Borthakur G; Verstovsek S; Faderl S; Cortes J; Kantarjian H
Cancer; 2009 Dec; 115(24):5746-51. PubMed ID: 19795507
[TBL] [Abstract][Full Text] [Related]
15. The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients.
Jiang X; Wang Z; Ding B; Yin C; Zhong Q; Carter BZ; Yu G; Jiang L; Ye J; Dai M; Zhang Y; Liang S; Zhao Q; Liu Q; Meng F
Oncotarget; 2015 Oct; 6(32):33612-22. PubMed ID: 26384351
[TBL] [Abstract][Full Text] [Related]
16. [Decitabine-cedazuridine as first line in acute myeloid leukaemia ineligible for conventional induction chemotherapy].
Tauveron-Jalenques U; Lambert J
Bull Cancer; 2024 May; 111(5):435-436. PubMed ID: 38582741
[No Abstract] [Full Text] [Related]
17. DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
Buelow DR; Anderson JT; Pounds SB; Shi L; Lamba JK; Hu S; Gibson AA; Goodwin EA; Sparreboom A; Baker SD
Clin Transl Sci; 2021 Jan; 14(1):137-142. PubMed ID: 32905646
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.
Ye XN; Zhou XP; Wei JY; Xu GX; Li Y; Mao LP; Huang J; Ren YL; Mei C; Wang JH; Lou YJ; Ma LY; Yu WJ; Ye L; Xie LL; Luo YW; Hu C; Niu LM; Dou MH; Jin J; Tong HY
Leuk Lymphoma; 2016; 57(6):1311-8. PubMed ID: 26372888
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia.
Becktell K; Houser K; Burke MJ
J Pediatr Hematol Oncol; 2019 Jan; 41(1):e38-e40. PubMed ID: 29668549
[TBL] [Abstract][Full Text] [Related]
20. Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use.
Santini V; Ossenkoppele GJ
Crit Rev Oncol Hematol; 2019 Aug; 140():1-7. PubMed ID: 31153036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
